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Introduction: The four countries in the Nordic Arthroplasty Register Association (NARA)
share geographic proximity, culture, and ethnicity. Pooling data from different sources in
order to obtain higher precision and accuracy of survival-probability estimates is appealing.
Nevertheless, survival probabilities of hip replacements vary between the countries. As such,
risk prediction for individual patients within countries may be problematic if data are
merged. In this study, our primary question was to address when data merging for estimating
prosthesis survival in subcategories of patients is advantageous for survival prediction of
individual patients, and at what sample sizes this may be advised.
Methods: Patients undergoing total hip replacements for osteoarthritis between January 1,
2000 and December 31, 2013 in the four Nordic countries were studied. A total of 184,507
patients were stratiﬁed into 360 patient subcategories based on country, age-group, sex,
ﬁxation, head size, and articulation. For each patient category, we determined the sample size
needed from a single country to obtain a more accurate and precise estimate of prosthesis-
survival probability at 5 and 10 years compared to an estimate using data from all countries.
The comparison was done using mean-square error.
Results:We found large variations in the sample size needed, ranging from 40 to 2,060 hips,
before an estimate from a single Nordic country was more accurate and precise than
estimates based on the NARA data.
Conclusion: Using pooled survival-probability estimates for individual risk prediction may
be imprecise if there is heterogeneity in the pooled data sources. By applying mean-square
error, we demonstrate that for small sample sizes, applying the larger NARA database may
provide a more accurate and precise estimate; however, this effect is not consistent and varies
with the characteristics of the subcategory.
Keywords: hip replacement, arthroplasty registry, merging data sets, variance, accuracy,
precision
Introduction
The Nordic Arthroplasty Register Association (NARA), comprising the national
arthroplasty registers of Denmark, Finland, Sweden, and Norway, has developed
a combined data set with a set of harmonized outcome deﬁnitions1 The NARA data
have successfully been used to predict outcomes and identify risk factors of hip and
knee replacements at the population level.1,2 The four Nordic countries share
geographic proximity in northern Europe. The ethnic origin in the countries is
also similar, and they have similar welfare and health-service models3 Still, within
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orthopedics, surgical practices, hospital surgery volume,
training of surgeons, prostheses in use, threshold for revi-
sion, and completeness of reporting of revisions are
different.1,2,4,5 These differences may explain the hetero-
geneity observed in survival estimates of total hip replace-
ments (THRs) between the countries.1,2
Pooling data from different sources in order to increase
sample size and obtain higher precision and accuracy of
survival-probability estimates is appealing when calculat-
ing individual risk predictions, as in risk calculators6
However, for this approach to be sensible, the different
sources should have similar survival probabilities. If the
survival probabilities differ, pooled estimates will not
represent any of the original sources of data, and will
thus have less accuracy. As such, using pooled estimates
for individual risk prediction may be imprecise if there is
heterogeneity in the pooled data sources. Mean-square
error (MSE) is a commonly used measure that accounts
for both accuracy and precision when comparing
estimates7 In this study, our primary question was to
address when data merging for estimating prosthesis sur-
vival in subcategories of patients is advantageous for sur-
vival prediction of individual patients, and at what sample
sizes this may be advised.
Study populations
Patients with THRs from the NARA held within the com-
mon database between January 1, 2000 and December 31,
2013 were included in the study.1,2 For homogeneity of
indication, only patients with osteoarthritis were included.
To avoid outdated prostheses, only THR operations with
frequently used contemporary cemented HR
stems (Lubinus, Exeter, Charnley, MS30, CPT, Müller,
and C-stem) and uncemented HR (Cone, SCP, Bimetric,
Bicontact, Corail, Versys, AML, CLS, ABG, Filler, and
Omniﬁt) brands were included.8,9 For both stems and cups,
all implants used in <500 operations within a country were
also removed from that country’s data set. Furthermore, all
stems and cups with <95% survival probability at 10-year
follow-up in any of the four countries were excluded to
minimize heterogeneity due to poorly performing
implants. These cutoffs were based on a UKNational
Institute for Health and Care Excellenceguideline10 For
the Finnish data, separate results for stems and cups were
not available. Therefore, stems and cups with overall sur-
vival (including all revision causes) <90% were excluded
from the Finnish part of the data. Metal-on-metal articula-
tion was considered noncontemporary and thus
excluded.11,12 The difference between highly cross-linked
polyethylene (XLP) and polyethylene has been identiﬁed
in the NARA database13 Radiation of 5 Mrad and more
was classiﬁed as XLP. For patients operated on for more
than one hip, only time to revision for the ﬁrst registered
primary operation was included. Based on the given cri-
teria, there remained 38,042 Norwegian, 14,385 Finnish,
21,439 Danish, and 110,641 Swedish patients. Therefore,
a total of 184,507 patients from the NARA data remained
for analyses (Figure 1).
The covariates availablefor the present analyses were:
age (20–59 years, 60–74 years, 75 years and older), sex,
prosthesis ﬁxation (cemented, uncemented, hybrid,
reversed hybrid), head size (<32 mm, 32 mm, >32 mm),
and articulation (metal + XLP, ceramic + XLP, ceramic +
Hip operations in the NARA data set:
n=620,261
Hip operations in the NARA with OA from January 1, 2000
to December 31, 2013:
n=400,313
Only included the first hip operation for patients operated
in both hips:
n=335,809
Only included patients with one of the following stems:
Lubinus, Exeter, Charnley, MS30, CPT, Müller,
C-stem THA, Cone, SCP, Bimetric, Bicontact, Corail,
Versys, AML, CLS, ABG, Filler or Omnifit.
Further, removed patients with stems and cups with
inferior survival probability at 10 years, or have been
used in fewer than 500 operations:
n=205,003
Removed patients with missing values for fixation type
or head size, and those with metal on metal articulation:
n=184,507
Figure 1 Flowchart for patients included in the study.
Abbreviations: NARA, Nordic Arthroplasty Register Association; OA, osteoarthritis.
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ceramic, metal + polyethylene, ceramic + polyethylene).
Table 1 summarizes the categories for the different vari-
ables. This categorization resulted in 360 combinations of
the covariates, and thus 360 patient subcategories.
Statistical methods
We aimed to quantify at what sample size for different
patient subcategories a country’s own data can be con-
sidered sufﬁcient in survival-probability calculations for
that country versus using the NARA database. For each
country, we compared 5- and 10-year survival-probability
estimates based on the country’s own data and estimates
based on the NARA data set. The procedure was equiva-
lent for all four countries and for the 5- and 10-years
survival-probability estimates, but explained only for
Norwegian data when analyzing 5-year survival-
probability estimates.
Norwegian patient subcategories with >250 patients
at risk at 5 years in both Norway and the NARA were
included. A cut off point at 250 patients at risk has
also been chosen in other studies, like Deere et al
(2019).14
We chose one of these patient subcategories. The
Kaplan–Meier survival-probability estimate at 5 years
was calculated with the available Norwegian data in
this subcategory and considered the correct Norwegian
survival probability (S) for this patient subcategory.
A small sample (starting at n=20) of random
Norwegian patients was drawn from the patient subcate-
gory and the Kaplan–Meier survival-probability estimate
at 5 years calculated. We named this the Norwegian
estimate: S^NOR of S.
Additionally, a survival-probability estimate based on
the corresponding data from the other NARA countries for
the patient subcategory, including the random sample from
Norway, was calculated. We named this the NARA esti-
mate: S^NARA of S.
The latter two steps were repeated 500 times in
a bootstrap-like simulation to obtain 500 Norwegian and
500 NARA estimates of S.
The MSE for the Norwegian estimate was then
calculated:
MSENOR ¼
1
500
ðS^NOR1  SÞ
2
þ ðS^NOR2  SÞ
2
þ . . .

þðS^NOR500  SÞ
2

:
The MSE for NARA was calculated applying the same
formula. MSE is deﬁned as the variance plus the square of
the bias for an estimator, and hence takes into account both
the accuracy (bias) and the precision (variance) of survi-
val-probability estimates7
MSE calculations were repeated, with sample sizes
increasing by 20 at each step. The MSE for the Norwegian
sample estimates will initially be large, due to low precision
(large variation due to small sample). After increasing the
sample size, the MSE for the Norwegian estimates will
eventually be lower than the MSE for NARA, since the
accuracy is less (the bias is larger) for the NARA estimates.
At this point, the Norwegian estimate is preferable.
The procedure described was repeated for all
Norwegian patient subcategories with >250 patients at
risk at 5 years.
R version 3.4.1 was applied for all analyses (www.
r-project.org).
Results
In Figure 2, the difference between the MSE for Norway
and the NARA as a function of sample size (for the sub-
category “female, age 60–74, cemented, head size <32 mm,
and metal + conventional polyethylene) is shown. This
ﬁgure shows that for approximately 1,460 patients, the
curve crosses zero for this subcategory. This implies that
for samples >1,460, the survival-probability estimate based
on the Norwegian sample has smaller MSE than the
Table 1 Different variables for total hip replacements
Age Sex Fixation Head size Articulation (head/cup)
20–59 years Male Cemented <32 mm M + XLP
60–74 years Female Uncemented 32 mm C + XLP
Over 74 years Hybrid >32 mm C + C
Reversed hybrid M + Poly
C + Poly
Notes: For articulation, the ﬁrst term gives the femoral head material, and the second the acetabulum bearing material.
Abbreviations: M, metal; C, ceramic; XLP, highly cross-linked polyethylene; Poly, conventional polyethylene.
Dovepress Bartz-Johannessen et al
Clinical Epidemiology 2019:11 submit your manuscript | www.dovepress.com
DovePress
521
estimate based on the NARA data. Therefore, for sam-
ples >1,460, the survival-probability estimate based on
a Norwegian sample is superior with regard to precision
and accuracy compared to the NARA estimate. This ﬁgure
illustrates the principle for the MSE calculations performed.
The same calculations were done for all patient subcate-
gories with >250 patients at risk at 5 and 10 years, respec-
tively (Supplementary Tables 1–7). We observed relatively
large variation in the sample size needed from a single
country to outperform the estimates based on the complete
NARA data. The number of patients needed before the
Norwegian estimates became more precise and accurate
compared to estimates based on the NARA data varied
from 120 to 960 at 5 years and from 140 to 2,060 at 10
years. For Denmark, the numbers were 80 and 440 at 5
years, respectively. At 10 years, there was no patient cate-
gory with sufﬁcient observations. For Finland, the numbers
were 100 and 400 at 5 years and 80 and 240 at 10 years. For
Sweden, the numbers were 40 and 1,880 at 5 years and 80
and 110 at 10 years (Supplementary Tables 1–7).
Discussion
In the present study, we compared survival-probability
estimates based on single Nordic countries versus esti-
mates based on the common database from the NARA to
determine whether amalgamation of data increase the
accuracy and precision of risk estimates. Using the MSE
approach, we demonstrated that for small samples apply-
ing the larger NARA database may provide a more precise
and accurate estimate. This effect is however inconsistent,
and varies with the characteristics of the subcategory
studied.
Our approach assumes a “true” survival of a certain
implant in a speciﬁc setting or in a regional hospital
environment. Another important aim with the NARA
initiative is that local factors, at least to a certain extent,
should be “leveled out”, supposing that data in the
compiled NARA database represent a more weighted
assessment of a speciﬁc implant and a more global
view. Further aims included studies of implants used in
small numbers in solitary countries or comparatively
rare outcomes in speciﬁc groups of patients. At an
early stage in the NARA process, we were also inter-
ested in local variations perhaps caused by differences
in hospital organization, local traditions, and possible
differences in patient demography, which are high-
lighted in this study.
There are many examples of successful merging of
data to generate overall survival estimates.5,11,15–17
Several studies have described validation and generaliza-
tion of individual risk-prediction algorithms.18–25
However, there is a difference between merging data to
obtain precise estimates with narrow conﬁdence intervals
and merging data from several databases for accurate and
precise risk prediction of single individuals (subcategories
of patients). The approach applied in this article is based
on a standard statistical principle used to obtain a sample
size when merging of data can be advantageous. MSE is
a standard tool in statistics for comparison of estimators,7
taking both precision and accuracy into account. We argue
that it is also a suitable tool for the present application.
This study has several strengths. We adjusted for indi-
vidual confounders to the extent that it was possible within
the NARA data set by stratifying patients into subcate-
gories according to the known covariates age, sex, ﬁxa-
tion, head size, and articulation to account for these
covariates in the estimates. Only patients with primary
osteoarthritis and contemporary prostheses with good
results were included, in order to reduce heterogeneity
across the study populations.
Our study also has limitations. Variables not cap-
tured within the NARA data set, including medical
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Figure 2 Norwegian MSE minus NARA MSE.
Notes: The patient category in this ﬁgure is “60–74 years old, female, cemented,
head size <32 mm, M + Poly”. The x-axis shows the sample size as explained in the
“Statistical methods” section. The y-axis shows the difference in MSE. The red
horizontal line is drawn at zero in order to visualize where the difference in MSE
crosses zero, and hence shows at what sample size the Norwegian estimate
becomes preferable with respect to the MSE.
Abbreviations: MSE, mean-square error; NARA, Nordic Arthroplasty Register
Association; M, metal; Poly, conventional polyethylene.
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comorbidities, differences in perioperative manage-
ment, revision thresholds, completeness of reporting,
and differences in choice of prosthesis subtypes and
head sizes within the three head-size categories chosen
for this study, also affect individual prediction of pros-
thesis survivorship. When considering merging of data
sets to enhance analytical power in individual-patient
risk-prediction tools, it is thus important to consider
the extent to which such confounders may be
accounted for within the applied data sets. Further,
the simulations done when calculating the MSE values
is a demanding task, and this may take several hours
depending on the equipment at hand.
In conclusion, using the MSE approach, we demon-
strated that for small samples, applying the larger NARA
database may provide a more accurate and precise esti-
mate; however, this effect is inconsistent and varies with
the characteristics of the subcategory studied.
Consent for publication
This study was approved through each national registry's
own ethical process. Patients in Norway gave individual
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the patient can opt not to participate.
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